Efficacy of abiraterone acetate for high-risk hormone-naïve metastatic prostate cancer: A comparison with combined androgen blockade therapy with bicalutamide and androgen deprivation therapy alone

<h4>Background</h4> The treatment landscape for men with metastatic hormone-naïve prostate cancer (mHNPC) has dramatically changed with the approval of next-generation anti-androgen drugs. We compared the treatment efficacy of abiraterone with that of combined androgen blockade (CAB) therapy and and...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Kent Kanao, Takayuki Takahashi, Yuta Umezawa, Takashi Okabe, Go Kaneko, Suguru Shirotake, Koshiro Nishimoto, Masafumi Oyama
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Public Library of Science (PLoS) 2022-01-01
coleção:	PLoS ONE
Acesso em linha:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584391/?tool=EBI
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!